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Sensitization directed to Human Leukocyte Antigens (anti-HLA)
is one of the major barriers to kidney transplantation. One
of the main reasons is the emergence of anti-HLA antibodies
(anti-HLAab) directed to previous transplants. The purpose of
this study was to investigate how the number incompatibilities
with previous transplants can affect sensitization of patients
re-entering on the waiting list for a 2nd transplant. The study
included a total of 243 patients who, after losing the first graft
re-entered our waiting list. Their sensitization was evaluated
using the results obtained by solid phase assays (SPA) (Single
Antigen Class 1 and 2), and using software that allows to calcu-
late the PRA against 2668 RANDOM HLA typing in following
loci: HLA-A, HLA-B,HLA-Cw, HLA-DR and HLA-DQ. When-
ever a patient had more than one SPA study the PRA attribute
to the highest result obtained. Patients were stratified into 7
groups according to the number of mismatches (MM) in HLA-A,
HLA-B and HLA-DR (0MM;1MM;2MM;3MM;4MM;5MM
and 6MM).The evaluation of mismatches was performed at
the broad level. The average PRA value of each group was
calculated. The number of patients included in each group
were respectively:1,13,63,97,48,18 and 3 and the results
obtained were: 0MM-PRA= 0%; 1MM-PRA= 78.3% [0-100];
2MM-PRA=85.3% [0-100]; 3MM-PRA=91.1% [0-100];
4MM-PRA= 91.7% [7-100]; 5MM-PRA= 99.6% [96.5-100]
and 6MM-PRA= 99.9%[99.9-100] (P= 0.0004). We also looked
in to the average days of survival of primary graft for each
group and the results obtained were as follows: 0MM= 4099
days; 1MM= 3367 days; 2MM= 2957 days; 3MM= 2843 days;
4MM= 2894 days; 5MM= 2754 days and 6MM= 2479 days.
Despite the low number of cases in some groups we can see that
the increasing number of mismatches is associated with a higher
value of PRA and with a lower graft survival. The higher PRA
value most certainly will contribute to a longer waiting time when
these patients reenter on our waiting list.
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Kidney allocation from cadaveric donors must balance two main
principles: medical utility and justice. The principle of medical
benefit is gauged by maximizing efficiency in the use of organs,
and the principle of justice by its effectiveness ensuring that all
patients have a reasonable opportunity to be transplanted. The sur-
vival benefit of transplant patients when compared with dialyzed
values is well described even after adjusting for age, comorbidi-
ties, albumin and Body Mass Index (BMI). This benefit is also
observed in patients over the age of 60 years. Several factors are
related to transplant efficiency: maximization of HLA matching
for patients that are more relevant (children and youth), prefer-
ence for children; minimization of ischemia time, and the rela-
tion of life expectancy of the graft with life expectancy of the
receptor. The factors related to justice are: reduction of waiting
times, and greater equity of access for patients regardless of their
race, blood group, HLA homozygosity and geographic location.
There are socio-demographic and immunological factors associ-
ated with longer waiting time for kidney transplantation, such as:
age, blood group or sensitization against HLA antibodies. Knowing
the prevalence and incidence (per year, per million inhabitants) of
kidney transplant candidates’ demographic factors such as: sex, age
groups, socioeconomic status, clinical and immunological charac-
teristics: blood group, PRA values, BMI, type of dialysis, cause of
renal failure, and comorbidities; allows for an objective compar-
ison of allocation programs. The waiting time for transplantation
should be measured as the median time between the start of dial-
ysis and transplantation of wait listed patients each year. By using
the Cox regression analysis, with time on dialysis to transplanta-
tion as a dependent variable and clinical and socio-demographic
factors as independent variables, will shed light on which charac-
teristics most affect the access to transplantation. Only by defining
and applying standardized metrics to kidney transplant candidates
over time, is it possible to make informed decisions when debating
organ allocation rules. “What gets measured gets improved”.
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The complement-fixing ability of HLA antibody, irrespective of
IgG MFI strength could be a key component of clinical outcome.
Recently, it has been developed a C1q-SAB assay that identi-
fies complement-fixing HLA antibodies with high sensitivity
and specificity. C1q is the first step in the classical complement
cascade activated by antibody and precedes C4d deposition.
IgG1/IgG3 activate complement and this response is triggered
when C1q binds to the Cγ2 region of IgG1/G3 and at the Cμ3
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